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Summary 
Diversity and mutations in the genes for outer surface  proteins (Osps) A and B ofBorrelia burgdorferi 
sensu lato (13, burgdorferi), the spirochetal agent of Lyme disease, suggests that a monovalent OspA 
or OspB vaccine may not provide protection against antigenically variable naturally occurring 
B, burgdorferi. We now show that OspA or OspB immunizations protect mice from tick-borne 
infection with heterogeneous/g burgdorferi from different geographic regions. This result is in 
distinct contrast to in vitro killing analyses and in vivo protection studies using syringe injections 
of/g burgdorferi as the challenge inoculum. Evaluations of vaccine efficacy against Lyme disease 
and other vector-borne infections should use the natural mode of transmission and not be predicated 
on classification systems or assays that do not rely upon the vector to transmit infection. 
V 
accination with outer surface proteins  (Osps)lA  or B 
from a Borrelia burgdorferi sensu  law (13, burgdorferi) iso- 
late (designated N40) protected C3H/HeJ mice from infec- 
tion when challenged with the same strain (1, 2). Humoral 
immunity was sufficient for protection as the passive transfer 
of OspA or OspB antibodies protected C.B.-17 scid or C3H 
mice from/3; burgdorferi infection (1-4). OspA and OspB vari- 
ability, including amino acid differences  or truncations of the 
COOH terminus of the Osps, however, allowed/~ burgdor- 
feri to survive in the presence of protective antibody in vitro 
and in vivo, predicting a lack of vaccine efficacy (2, 5-11). 
In addition, spirochetes  have  been identified that lack the 49-kb 
plasmid encoding ospA and ospB or have chimeric Osps due 
to homologous recombination between ospA  and ospB, sug- 
gesting that OspA or OspB mediated immunity would not 
be protective in the event of infection by these mutants (7, 
12). The infectivity of these mutant spirochetes in selected 
hosts has not yet been delineated. RFLP, multilocus enzyme 
electrophoresis, or nucleic acid hybridization  studies distin- 
guished as many as four groups of/t burgdorferi,  with the 
1  Abbreviation used in this paper: Osp, outer surface  protein. 
215 
description of three new proposed species-/g burgdorferi sensu 
stricto, Borrelia afzelii,  and Borrelia garinii (13-17). Similarly, 
reactivity with OspA mAbs divided/g burgdorferi into seven 
serogroups which upon detailed analysis (several of the sero- 
types were variants of the three species that arose from osp 
recombination)  corresponded to the three new species (13). 
lg burgdo~feri sensu stricto is prevalent in North America whereas 
European sites may contain all three species. In vivo passive 
immunization studies demonstrated that antiserum  against 
spirochetes from individual groups protected scid mice or ham- 
sters against challenge with homologous, but not heterolo- 
gous/~  burgdorferi (8,  18). 
The in vivo protection studies used single isolates of/~ burg- 
dorferi, and syringe inoculations as the method of spirochete 
challenge, and therefore do not mimic natural transmission 
of the agent. Accordingly, we have shown that vaccination 
with OspA (from R  burgdorferi N40) protected mice when 
fed upon by lxodes dammini that were experimentally infected 
with/~ burgdorferi N40 or by naturally infected ticks collected 
on Nantucket, MA (19, 20). We observed a dual mode of 
vaccine action-killing of the spirochetes within the host and 
direct destruction of spirochetes within the vector. The prev- 
alence ofB. burgdorferi with variable Osps, the rate ofosp mu- 
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Volume 181  January  1995  215-221 tations  within  ticks,  the  number  of different B.  burgdorferi 
isolates and their relative concentrations in individual ticks, 
and the infectivity and pathogenicity of different isolates, rep- 
resent variables that may influence monovalent vaccine efficacy. 
We now determine whether OspA or OspB immunization 
protects mice from tg burgdorferi infection transmitted by ticks 
infected with spirochetes isolated from diverse geographic lo- 
cations  and  within  different  taxonomic  groups. 
Materials and Methods 
M/c~  4-wk-old female C3H/HeJ mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME). The animals were shipped 
and housed in micro-isolator cages. The water was provided daily, 
and the animals were euthanized with carbon dioxide. 
R  burgdo~ri  isolates  were  grown  to  log  phase  in  modified 
Barbour-Stoenner-Kelly II medium, and counted using a hemo- 
cytometer under darkfield microscopy. 
Immunoblot Analysis.  3/~g of boiled R  burgdo~fer/ were sepa- 
rated by SDS-PAGE  and transferred to nitrocellulose. R  burgdor- 
fir/, OspA, and OspB antiserum or mAbs to OspA or OspB were 
diluted (1:100) and incubated with the nitrocellulose strips.  The 
strips were washed, incubated with a 1-5,200 dilution of alkaline 
phosphatase-labeled goat anti-mouse (or rabbit) IgG, and devel- 
oped with nitroblue tetrazoleum and 5-bromo-4-chloro-3-indolyl- 
phosphate, as described  (5). 
Vaccination Studies.  Groups of female C3H/HeJ mice were im- 
munized subcutaneously with 10/~ of recombinant OspA or OspB 
(both expressed  as glutathione  transferase [GT] fusion proteins) 
in CFA and boosted at 14 and 28 d with the same amount in IFA 
(1). Control mice were immunized with 10/~g of recombinant GT 
with the same regimen. For studies of R  burgdorferi infection of 
mice transmitted by ticks, animals were challenged with 13, burg- 
dorfer/-infected  ticks.  2 wk after the last booster immunization, 
five nymphal ticks were placed on each mouse. Ticks were allowed 
to feed to repletion (72-96 h), naturally detach, and were collected 
over a water bath as described (19). Mice were killed 2 wk after 
the retrieval  of ticks from the water.  For passive immunization 
studies,  mice were immunized with 0.2 ml of selected OspA and 
OspB mAbs. Passively immunized mice were challenged intrader- 
mally with  105 R  burgdo~r/1  d  after the immunization.  Mice 
were killed  14 d  after challenge inoculation. 
Immunofluorescence of Tick Lysates.  Ticks were examined for 
R  burgdorferi by direct immunofluorescence of tick lysates  with 
rabbit anti R  burgdo~f~ serum as described (20). Tick lysates (100/~1) 
were placed on slides, immersed in acetone for 10 min, and then 
air dried for 10 min.  FITC-conjugated rabbit anti-R  burgdo~ri 
(10 mg/ml), used at a dilution of 1:100, was placed on the slides 
and allowed  to incubate for 30 min at 37~  and then washed 
Table  1.  Efficacy of OspA or OspB  Vaccine Mediated Protection against Tick-transmitted Infection 
with B.  burgdorfer/ from Different Geographic Regions 
B.  burgdorferi origin  Immunogen  Culture  Disease  Infection  Chi  square 
Northeast  US  OspA  0/4  0/4  0/4 
OspB  0/4  0/4  0/4  p  ~<0.001 
Control  4/5  5/5  5/5 
California  OspA  0/12  0/12  0/12 
OspB  0/12  0/12  0/12  p  ~0.01 
Control  4/10  5/10  5 / 10 
Sweden  OspA  0/12  0/12  0/12 
OspB  0/11  0/11  0/11  NS 
Control  0/12  1/12  1/12 
Germany  OspA  0/10  0/10  0/10 
OspB  4/10  4/10  4/10  p  ~<0.001 
Control  8/10  10/10  10/10 
JD-1  OspA  0/5  0/4  0/5 
Control  4/5  5/5  5/5  p  ~<0.001 
20001  OspA  0/5  0/5  0/5 
Control  3/5  3/5  3/5  p  ~<0.05 
pGau  OspA  0/10  0/10  0/10 
NS 
Control  0/10  0/10  0/10 
We immunized mice with OspA or OspB GT fusion proteins or GT (controls). Mice were evaluated for infection by culture of the blood, spleen, 
bladder, and skin, and histopathology (arthritis and carditis). We tabulated the number of infected mice per number of mice examined, based on 
culture and disease. 
216  Vaccination  against Diverse R  burgdorferi-caused Lyme Disease Table  2.  Destruction of B.  burgdolferi within  Ticks  that Fed on Immunized Mice 
B.  burgdorferi origin  Immunogen  No. infected ticks/No,  ticks examined  Chi square 
Northeast  US  OspA  0/6 
OspB  1/9  p g0.05 
Control  5/12 
California  OspA  0/14 
OspB  0/14  p ~g0.05 
Control  4/14 
Sweden  OspA  0/5 
OspB  0/7  p ~g0.05 
Control  4/9 
Germany  OspA  6/29 
OspB  6/21  p ~g0.001 
Control  22/30 
JD-1  OspA  1/12  p g0.001 
Control  9/11 
20001  OspA  0/7  p g0.05 
Control  4/8 
pGau  OspA  1/8  NS 
Control  5/14 
The ticks were evaluated for B. burgdorferi 10 d after engorgement to repletion. Ticks lysates were examined for B. burgdolferi by direct and indirect 
immunofluorcence, using FITC-labeled rabbit anti-B, burgdo~feri sera or flagellin mAb H9724 as described (19, 20). 
three times in water, after which the stained spirochetes were visual- 
ized by fluorescence microscopy. 
RFLP Analysis.  Total  genomic DNA was extracted from/~ burg- 
dorferi strains as described (15) and 5 pg of DNA was digested with 
100 U of restriction endonuclease according to the manufacturer's 
recommendations (Boehringer Mannheim, Mannheim, Germany). 
Samples were subjected to electrophoresis on a 0.7%  agarose gel 
and the DNA fragments were transferred to nitrocellulose. Hy- 
bridization  with 32p-labeled probes was done overnight at 65~ 
in 0.5 M NaHPO4, 7% SDS, pH 7.2, at room temperature  for 
30 min, and dried. The membranes were developed by autoradiog- 
raphy. OspA  and flagellin probes were prepared as previously de- 
scribed (15). 
Results and Discussion 
We collected infected Ixodes ticks from selected distant geo- 
graphic locations for use in vaccination studies. The/~ burg- 
dorferi infection rates in ticks from the Northeastern United 
States,  California,  Germany, or Sweden were 35, 5, 12, and 
16%  respectively. The low prevalence of spirochetal infec- 
tion in host-seeking ticks from European and Californian sites 
precluded the possibility of using these field-collected ticks 
for the challenge experiments. Accordingly, we generated our 
challenge ticks by experimental infections that simulated the 
natural process of infection as closely as possible. Challenge 
ticks containing spirochetes  from California, Sweden, or Get- 
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many were derived by allowing nymphal Ixodespacificus  (from 
California) or Ixodes ricinus (Sweden or Germany) that had 
been swept from vegetation to feed on hamsters (California 
or Sweden) or gerbils (Germany), and these hosts then served 
as the source of infection for larval I. dammini (for California 
or Sweden) or I. ricinus (for Germany).  In this manner,  we 
were able to insure that spirochetes infected most of our chal- 
lenge ticks; a median of 50% of all nymphs that were used 
in these experiments contained spirochetes. We also infected 
ticks with isolates representing/g burgdorferi sensu stricto (JD1 
and 20001) or/g afzelii (pGau)-type spirochetes with different 
degrees of infectivity in the C3H mouse-JD1,  20001, and 
pGau are highly, moderately, and poorly infectious in this 
model system, respectively./~ garinii  (i.e.,  isolate pBi) that 
we have tested are not infectious in C3H mice, therefore, we 
have not included these spirochetes in our protection studies. 
JD1 was maintained in continuous tick-mouse-tick passage 
since its derivation from a group of nymphal I. dammini col- 
lected from Crane Beach, MA (21), 20001 was isolated from 
a field swept I. ricinus in Brittany, France (22), and pGau was 
isolated from the skin of a patient with acrodermatitis chronica 
atrophicans (23). 
We then determined whether vaccination with OspA or 
OspB (from/~  burgdorferi N40) protected mice from infec- 
tion with R  burgdorferi from different regions.  Immuniza- 
tion with OspA fully protected mice from infection by ticks containing/~ burgdorferi from the Northeastern United States, 
California, or Germany (Table 1). The Northeastern United 
States and German isolates efficiently infected all control mice 
whereas the Californian isolates were recovered from 50% 
of the control mice. OspA-mediated protection extended to 
mice fed upon by ticks containing JD-1 or 20001 spirochetes, 
as well. OspB vaccination protected mice from infection by 
lg  burgdorferi  from the Northeastern United States or Cali- 
fornia, and provided partial protection against German/t burg- 
dorferi.  The Swedish or pGau spirochetes were not readily 
transmitted by ticks to C3H mice (only one control animal 
developed disease) so we could not directly evaluate protection. 
Analysis of tick lysates by immunofluorescence  showed that 
spirochetes were eliminated directly within ticks that fed on 
Osp-vaccinated mice, regardless of whether the B. burgdorferi 
originated from the Northeastern United States, California, 
or Sweden, or were JD-1  or 20001  spirochetes (Table  2). 
Significant destruction of German or pGau spirochetes oc- 
curred in ticks that fed on Osp-immunized mice. Thus the 
immune response to heterologous OspA or OspB is sufficient 
to kill/~ burgdoCeri within the vector regardless of their origin. 
Such destruction correlates strongly with protection and allows 
us to infer that protection with our monotypic antigens may 
be broadly protective. 
We determined the extent of genetic heterogeneity within 
1t  burgdorferi that had been cultured from ticks that had fed 
on the control mice by means of ILFLP analysis (15) (Table 
3). 21 United States tick isolates were tested; all were/g burg- 
dorferi sensu stricto (RFLP group 1) type organisms. The sole 
exceptions were one California isolate and the JD-1  strain 
(21) which were considered to be/t  burgdorferi  sensu  stricto 
variants because of the presence of additional faint bands on 
Southern blot. These bands may be due to osp recombina- 
tion, as has been observed with strain JD-1 (Lobet, Y., un- 
published data) or OspA variability within/g burgdo~ri sensu 
stricto  such as occurs with/~  burgdorferi  25015  (5,  15). All 
11 German or Swedish isolates tested were B  afzelii  (RFLP 
group 4) type spirochetes./g garinii were not recovered from 
our studies and this may reflect the geographic regions used 
or the poor infectivity of/~ garini organisms in the hamsters 
or gerbils that initially served as hosts for the collected ticks. 
Vaccination with a single OspA or OspB antigen therefore 
protected mice against naturally occurring/g burgdoCeri within 
different taxonomic groups, suggesting that immunity against 
vector-borne Lyme borreliosis is likely to be more compre- 
hensive than previously believed. 
We determined the antigenic and immunologic heteroge- 
neity of OspA and OspB from 32 selected cultures from our 
tick transmission studies by probing the/~  burgdorferi with 
selected mAbs (against/g burgdorferi N40) that bind to different 
epitopes on B. burgdorferi N40 OspA or OspB (Fig.  1). OspA 
mAb CIII.78 and OspB mAb 7E6C protected mice from in- 
fection in passive immunization studies and bound to COOH- 
terminal conformational epitopes, whereas OspB mAb B10 
was not protective and recognized an epitope at the NH2 
terminus (1, 20, 24). We generated other Osp mAbs (against 
lg  burgdorferi N40) and now show that OspA mAb IX.D11 
protects mice from infection in passive immunization studies 
Table  3.  Immunoblot and RFLP Analyses of Selected B.  burgdorferi Recovered from Selected  Ticks 
or Mice  Used in Immunization  Studies 
Immunoblot  with Osp antibodies 
B.  burgdorferi  OspA mAb 
isolate  RFLP type  8C4BC  CIII.78  IX.Dll 
OspB mAb 
B10  22J  27G  7E6C 
California 1-8  B.  burgdorferi sensu stricto  +  +  +  +  +  +  + 
(KFLP group 1) 
California 9  B.  burgdorferi  sensu stricto  variant  +  +  +  +  +  +  + 
(KFLP group 1 variant) 
Northeast  US 1-12  B.  burgdorferi  sensu stricto  +  +  +  +  +  +  + 
(KFLP group 1) 
Germany 1-6  B.  afzelii  +  -  -  +  +  +  - 
(KFLP group 4) 
Sweden 1-5  B  afzelii  +  -  -  +  +  +  - 
(R.FLP group 4) 
JD-1  B.  burgdorferi  sensu stricto  variant  +  +  +  +  +  +  + 
(KFLP group 1 variant) 
RFLP analysis  of B. burgdorferi  DNA, digested with HindllI and probed with radiolabeled  ospA andflagellin was performed as described and correlated 
with the three newly described B.  burgdorferi species: B.  burgdorferi sensu stricto, B. afzelii, and B, garini (16). Immunoblots were performed using 
OspA and OspB mAbs as described. 
218  Vaccination  against Diverse/~  burgdorferi-caused Lyme Disease Figure 1.  Immunoblots of different/~ burgdorferi probed with various monoclonal and polyclonal antibodies to/g burgdo~ri N40 OspA and OspR 
(A and/'/) OspA mAb 8C4BC. (B) OspA mAb CIII.78.  (C) OspA mAb IX.DII. (D) OspB mAb B10, (E and/) OspB mAb 22J. (F and.]) OspB 
mAb 27G. (G and K) OspB mAb 7E6C. (L) Rabbit OspA antiserum. (M) Rabbit OspB antiserum. (A-G) Lane 1, California/g burgdorferi; lane 2, 
Northeastern/~  burgdo~feri;  and lane  3, Swedish/~ burgdorferi. (H-M) Lanes  I-4, German B. burgdorferi. The mohcular masses  are described  in kilodaltons. 
(N) Diagram depicts the regions of OspA or OspB to which the various mAbs bind.  The binding epitopes of OspA or OspB are shown in black 
and the corresponding amino acids are numbered. 
(Chi square test, p gO.001), whereas OspA mAb 8C4BC and 
OspB mAbs 22J and 27G did not have protective capabilities 
against/~  burgdorferi infection (2) (Table 4).  mAb IX.D11 
bound to  a COOH-terminal epitope  of OspA  and mAbs 
8C4BC, 22J, and 27G bound the NH2 terminus or central 
region of OspA or OspB (2, 24). All of the Osp mAbs bound 
to  all 21  of the Northeastern and Californian  spirochetes 
whereas  protective  mAbs  (OspA  mAbs  CIII.78  and and 
IX.DII and Osp B mAb 7E6C) did not bind with/~ burgdor- 
fer/from Germany and Sweden (Fig. 1). Some mAbs showed 
219  Fikrig et al. Table  4.  Passive Immunization  of Mice against Challenge 
with B.  burgdo~eri N40 
Passive immunization  B burgdorferi infection 
Ospa mAb 
CIII.78  0/5 
IX.Dll  0/5 
8C4BC  5/5 
OspB mAb 
7E6C  0/5 
22J  5/5 
27G  5/5 
The passive transfer of antibody and challenge of mice with a syringe 
inocula of B. burgdorferi  was performed as described  and B. burgdorferi  in- 
fection was documented  by recovery  of spirochetes from cultures of the 
animals blood, spleen, bladder, or skin and/or histopathologic evidence 
of arthritis or carditis. 
binding to more than one band of some/i burgdorferi on im- 
munoblot, further showing antigenic differences among the 
spirochetes- these may represent truncated Osps or antigens 
that arose from osp recombination (2, 7, 12, 13). These data 
suggest that there are conserved regions of OspA and OspB 
that are recognized by some protective antibodies in all/i burg- 
do~eri isolates tested. Indeed polyclonal rabbit anti OspA-N40 
or anti OspB-N40 reacts with all the United States, Swedish, 
and German isolates tested; a representative  immunoblot from 
four German strains  demonstrates  the strong reactivity we 
observed with all of our challenge isolates (Fig.  1, L and M). 
Immunization  against tick-borne Lyme borreliosis using 
a single recombinant OspA or OspB appears to be more effica- 
cious than would be expected on the basis of/i  burgdorferi 
classification  systems, in vitro killing assays, or in vivo studies 
using syringe-mediated challenge.  Therefore, destruction of 
t3, burgdorferi within the tick before spirochete transmission 
may be the main mode of protection  and may depend on 
less specific interactions than those observed within the ver- 
tebrate host. In cases where partial eradication of spirochetes 
occurred in ticks, the pathogenicity of the remaining/i  burg- 
dorferi and  the ability of partially debilitated organisms  to 
transmit disease may be diminished.  Indeed,/g burgdorferi  with 
a truncated OspB have reduced infectivity in mice (25).  Al- 
though such spirochetes may evade Osp-mediated protection 
in  the tick,  the clinical  significance  of infection by poorly 
infectious or avirulent spirochetes is unclear.  Therefore it may 
not be necessary to elicit a protective immune response against 
13, burgdorferi, with atypical Osps that may occur in nature. 
In addition,  the cross-protective effect may be due to anti- 
bodies that bound to conserved epitopes among the/g burg- 
dorferi isolates-these antibodies may not be overtly protec- 
tive in standard syringe inoculation and in vitro assays but 
are sufficiently effective within  the tick.  Studies of immu- 
nity to other major vector transmitted diseases such as malaria 
and leishmaniasis  rely, for the most part, upon artificial labo- 
ratory studies that  may greatly influence the experimental 
outcome. The natural mode of transmission should be used 
in  studies of vaccination  against  vector-borne agents. 
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